Professor of Medicine, Harvard Medical School
Hematology
Dr. Kenneth A. Bauer, MD
|
|
Give Review
Kenneth A. Bauer practices Hematology. He went to medical school at Stanford University School of Medicine. Stanford University School of Medicine is a top medical university. Stanford University School of Medicine is ranked 2 in research and 25 in primary care medicine He has 1 awards "Elected Member". Kenneth Bauer is a published doctor. He published 49 publications, including: 'How Long Is Long Enough? Extended Anticoagulation for the Treatment of Cancer-Associated Deep Vein Thrombosis.'
Publications
- How Long Is Long Enough? Extended Anticoagulation for the Treatment of Cancer-Associated Deep Vein Thrombosis.
- Stroke Prevention in Atrial Fibrillation in Older Adults: Existing Knowledge Gaps and Areas for Innovation: A Summary of an American Federation for Aging Research Semi...
- Dabigatran, ROCKET atrial fibrillation, and beyond: basic science, mechanisms of agents, monitoring, and reversal.
- Prevention and treatment of venous thromboembolism in pregnancy in patients with hereditary antithrombin deficiency.
- Prediction and prevention of thromboembolic events with enoxaparin in Cancer patients with elevated tissue factor-bearing microparticles: a randomized-controlled phase...
- Assessing the risk of venous thromboembolic events in women taking progestin-only contraception: a meta-Analysis.
- Reversal of antithrombotic agents.
- ACP Journal Club. Enoxaparin thrombophylaxis did not reduce mortality in Acutely ill medical patients.
- Recent progress in anticoagulant therapy: oral direct inhibitors of thrombin and factor Xa.
- Long-term management of venous thromboembolism: a 61-year-old woman with unprovoked venous thromboembolism.
- Thrombophilias in pregnancy.
- Platelet function following administration of a novel formulation of intravenous diclofenac sodium versus active comparators: a randomized, single dose, crossover stud...
- Thrombophilia evaluation: the value of testing relatives.
- The use of antithrombotic therapies in the prevention and treatment of arterial and venous thrombosis: a survey of current knowledge and practice supporting the need f...
- New oral anticoagulants in development: potential for improved safety profiles.
- Duration of antiCoagulation: applying the guidelines and beyond.
- Tumor-derived tissue factor-bearing microparticles are associated with venous thromboembolic events in malignancy.
- Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial.
- Long-term anticoagulant therapy for idiopathic pulmonary embolism in the elderly: a decision Analysis.
- New anticoagulants.
- Population pharmacokinetics and pharmacodynamics of rivaroxaban--an oral, direct factor Xa inhibitor--in patients undergoing major orthopaedic surgery.
- Venous thrombosis in the elderly: more questions than answers.
- Rivaroxaban for thromboprophylaxis after orthopaedic surgery: pooled Analysis of two studies.
- Obstetric complications in patients with hereditary thrombophilia identified using the LCx microparticle enzyme immunoassay: a controlled study of 5,000 patients.
- The thrombospondin-1 N700S polymorphism is associated with early myocardial infarction without altering von Willebrand factor multimer size.
- Asymptomatic factor VII deficiency in African Americans.
- The role of other hemostatic factors in predicting arterial thrombotic events.
- BAY 59-7939: an oral, direct factor Xa inhibitor for the prevention of venous thromboembolism in patients after total knee replacement. A phase II dose-ranging study.
- Assessment of hemostatic risk factors in predicting arterial thrombotic events.
- Role of thrombophilia in deciding on the duration of antiCoagulation.
- Fondaparinux.
- The use of recombinant activated factor VII in three patients with central Nervous system hemorrhages associated with factor VII deficiency.
- Superiority of fondaparinux over enoxaparin in preventing venous thromboembolism in major orthopedic surgery using different efficacy end points.
- New pentasaccharides for the prophylaxis of venous thromboembolism: clinical studies.
- New pentasaccharides for prophylaxis of deep vein thrombosis: pharmacology.
- Coagulation activation and long-term outcome in Acute coronary syndromes.
- Fondaparinux, the first selective factor Xa inhibitor.
- Use of recombinant human antithrombin in patients with congenital antithrombin deficiency undergoing surgical procedures.
- Fondaparinux: basic properties and efficacy and safety in venous thromboembolism prophylaxis.
- Clinical utility of factor V leiden (R506Q) testing for the diagnosis and management of thromboembolic Disorders.
- Fondaparinux vs enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery: a meta-Analysis of 4 randomized double-blind studies.
- Factor Xa inhibition in the prevention of venous thromboembolism and treatment of patients with venous thromboembolism.
- Hormone replacement therapy and the factor V Leiden mutation.
- Selective inhibition of Coagulation factors: advances in antithrombotic therapy.
- Fondaparinux, a synthetic pentasaccharide: the first in a new class of antithrombotic agents - the selective factor Xa inhibitors.
- A new antithrombotic strategy, the selective inhibition of Coagulation factors, and its importance to the orthopedic specialist.
- A meta-Analysis of fondaparinux versus enoxaparin in the prevention of venous thromboembolism after major orthopaedic surgery.
- Hypercoagulability: too many tests, too much conflicting data.
Schools
Stanford University
Chicago Hosps
Dana Farber Cancer Institute
Conditions Treated
- Acute Leukemia
- Anal and Rectal Cancer
- Anemia
- Brain and Nervous System Cancer (incl. Gliomas, Astrocytoma, Schwannoma, Medulloblastoma, Chordoma)
- View All
Doctors Specialties
- Medical Oncology
- Oncology
- Hematology
Accepted Insurances
Awards
- Elected Member
Education
-
University of Chicago -
Stanford University School of Medicine
Hospital
-
Beth Israel Deaconess Medical Center
Drug Facts
| NPI NUMBER | 1558309849 | |
| NPPES Provider LastName | BAUER | |
| NPPES Provider FirstName | KENNETH | |
| NPPES Provider ZIPCode | 02132 | |
| NPPES Provider State | MA | |
| Specialty Description | Internal Medicine | |
| Total Claim Count | 78.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1558309849 |
| Last Name Of The Provider | BAUER |
| First Name Of The Provider | KENNETH |
| View All |
Similar Doctors
|
|
Dr. Richard T. Penson, MD
 This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Edgar C. Henshaw |
|
|
Dr. Benjamin J. Drapkin, MD |
|
|
Dr. Nikhil Wagle, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Brendan D. McNulty, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Leena Gandhi, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Robert I. Handin, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jeffrey W. Clark, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Rachel A. Freedman, MD
This Doctor is OpenDoctor Recommended.
|